Rhumbline Advisers bought a new stake in shares of Cellular Biomedicine Group Inc (NASDAQ:CBMG) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,650 shares of the biotechnology company’s stock, valued at approximately $208,000. Rhumbline Advisers owned about 0.06% of Cellular Biomedicine Group at the end of the most recent reporting period.

Separately, Tibra Equities Europe Ltd acquired a new position in shares of Cellular Biomedicine Group during the first quarter valued at approximately $487,000. Institutional investors own 8.31% of the company’s stock.

NASDAQ:CBMG opened at $23.65 on Wednesday. Cellular Biomedicine Group Inc has a one year low of $9.15 and a one year high of $24.10.

Cellular Biomedicine Group (NASDAQ:CBMG) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.01). Cellular Biomedicine Group had a negative net margin of 10,133.88% and a negative return on equity of 47.52%. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. research analysts predict that Cellular Biomedicine Group Inc will post -2.14 EPS for the current fiscal year.

CBMG has been the subject of a number of research analyst reports. ValuEngine raised Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Zacks Investment Research raised Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a report on Tuesday, May 29th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Cellular Biomedicine Group in a report on Friday, June 15th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $32.00.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.

Featured Article: S&P 500 Index

Want to see what other hedge funds are holding CBMG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellular Biomedicine Group Inc (NASDAQ:CBMG).

Institutional Ownership by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.